Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | AFFX, LIFE, & OTC-PWRM:Affymetrix Launches Axiom Custom Genotyping Arrays Utilizing World's LargestAFFX, LIFE, & OTC-PWRM: Affymetrix Launches Axiom Custom Genotyping Arrays Utilizing World's Largest Validated SNP Database
By: Blayne Sheffield Affymetrix Inc. reported today that based on financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company’s previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million. Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Visit: http://www.affymetrix.com _____________________________________________ Life Technologies Corporation Life Technologies is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference. Please visit our website: http://www.lifetechnologies.com. ___________________________________ POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB) PWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum. PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover: Processes - The manner in which the discoveries are made and tests developed Discoveries - Protein disease footprints, Products - Early detection tests, Biomarkers, and Drug Targets The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance: The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below: Two of Power3 Medical Areas of Research Breast Cancer Power3’s early indication breast cancer NAF protein footprint test More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer NAF footprints for individualized therapy Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders Power3’s blood serum test for distinguishing between the neurodegenerative diseases Blood serum biomarkers and drug targets for neurodegenerative disease Resistance to Chemotherapy Power3’s test for prediction of response to drug therapy in cancer Biomarkers and drug targets for treatment and monitoring of drug resistance Continue your research at www.power3medical.com ******************************************* Sign-Up For Free Stock Alerts At http://crwepicks.com/ ******************************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/ ******************************************* # # # Crown Equity Holdings Inc. assists and consults with domestic and foreign companies interested in becoming publicly traded in the U.S. The company designs and manufactures multi-monitor computer systems for financial traders and audio/video professionals. End
Account Email Address Disclaimer Report Abuse
|
|